Are GLP-1 Drugs Becoming a Meaningful Revenue Driver for CAH Stock?

Key Takeaways Cardinal Health saw GLP-1 drugs add about six percentage points to segment revenue growth in Q2 FY26.CAH benefits from strong demand in injectable GLP-1s, driving higher distribution volumes across pharma.Oral GLP-1 adoption may grow over time, supporting sustained top-line gains despite modest profit impact.Cardinal Health (CAH) is clearly benefiting from the rapid adoption of GLP-1 therapies, though the impact remains more pronounced on revenues than profitability. In the second quarter of f ...